Moderna gave its mRNA-based seasonal flu vaccine to the first set of volunteers in a clinical trial, the pharmaceutical company announced today. The start of the trial marks the next stage of the company’s work on this type of vaccine technology after the overwhelming success of its COVID-19 vaccine, which was built using the same strategy. Before the COVID-19 pandemic, mRNA vaccines were still largely experimental, even as they were heralded as the future of vaccine development. People who get an mRNA vaccine are injected with tiny snippets of genetic material from the target virus. Their cells use that genetic information to build bits of the virus, which the body’s immune system learns to fight against. The high efficacy of the mRNA COVID-19 vaccines made by Moderna and Pfizer / BioNTec...
The US is to distribute half a billion shots of the Pfizer vaccine to nearly 100 poorer countries. Some 200 million doses will be given out this year and 300 million in 2022. It comes as US President Joe Biden said before leaving for the G7 summit in Cornwall that he would be announcing a vaccine strategy for the world. The US would pay for the doses at a “not-for-profit” price, according to the New York Times, which said the plan could be officially announced on Thursday. The shots will go to 92 lower-income countries and the African Union, sources told the Reuters news agency. Pfizer and the White House have so far not officially commented. America is well advanced in its vaccine rollout but campaigners have called for richer countries to do more to help protect developing nations. It’s ...
The coronavirus variant discovered in South Africa may evade the protection provided by Pfizer/BioNTech’s COVID-19 vaccine to some extent, a real-world data study in Israel found, though its prevalence in the country is very low and the research has not been peer reviewed. The study, released on Saturday, compared almost 400 people who had tested positive for COVID-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinated patients with the disease. It matched age and gender, among other characteristics. The South African variant, B.1.351, was found to make up about 1% of all the COVID-19 cases across all the people studied, according to the study by Tel Aviv University and Israel’s largest healthcare provider, Clalit. But among patient...
South Africa has signed an agreement with Johnson & Johnson to secure 11 million COVID-19 vaccine doses and will ease restrictions due to a decline in new cases, President Cyril Ramaphosa said on Sunday. South Africa has been the hardest-hit on the continent by the pandemic, recording almost half of the COVID-19 deaths and more than a third of reported infections. But daily cases have fallen below 2,000, from a peak above 20,000 last month during a second wave of infections. Ramaphosa said in a televised address that 2.8 million of the J&J doses would be delivered in the second quarter, with the rest spread throughout the year. South Africa started administering the single-dose J&J vaccine this month in a research study targeting healthcare workers but has not yet rolled out sh...